Equity Overview
Price & Market Data
Price: $3.09
Daily Change: +$0.0206 / 0.67%
Daily Range: $3.07 - $3.13
Market Cap: $8,764,927
Daily Volume: 3,410
Performance Metrics
1 Week: -12.29%
1 Month: 127.4%
3 Months: 7.34%
6 Months: -32.53%
1 Year: -53.23%
YTD: 23.29%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.